Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1986 3
1987 1
1988 1
1989 3
1990 2
1991 1
1993 3
1994 6
1995 4
1996 11
1997 4
1998 8
1999 8
2000 13
2001 3
2002 14
2003 23
2004 24
2005 26
2006 30
2007 36
2008 44
2009 56
2010 47
2011 64
2012 69
2013 99
2014 113
2015 136
2016 151
2017 157
2018 155
2019 203
2020 270
2021 302
2022 340
2023 315
2024 151

Text availability

Article attribute

Article type

Publication date

Search Results

2,555 results

Results by year

Filters applied: . Clear all
Page 1
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL; IMbrave150 Investigators. Finn RS, et al. Among authors: zhu ax. N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745. N Engl J Med. 2020. PMID: 32402160 Clinical Trial.
Evolving therapeutic landscape of advanced hepatocellular carcinoma.
Yang C, Zhang H, Zhang L, Zhu AX, Bernards R, Qin W, Wang C. Yang C, et al. Among authors: zhu ax. Nat Rev Gastroenterol Hepatol. 2023 Apr;20(4):203-222. doi: 10.1038/s41575-022-00704-9. Epub 2022 Nov 11. Nat Rev Gastroenterol Hepatol. 2023. PMID: 36369487 Review.
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma.
Zhu AX, Abbas AR, de Galarreta MR, Guan Y, Lu S, Koeppen H, Zhang W, Hsu CH, He AR, Ryoo BY, Yau T, Kaseb AO, Burgoyne AM, Dayyani F, Spahn J, Verret W, Finn RS, Toh HC, Lujambio A, Wang Y. Zhu AX, et al. Nat Med. 2022 Aug;28(8):1599-1611. doi: 10.1038/s41591-022-01868-2. Epub 2022 Jun 23. Nat Med. 2022. PMID: 35739268
Precision treatment in advanced hepatocellular carcinoma.
Yang X, Yang C, Zhang S, Geng H, Zhu AX, Bernards R, Qin W, Fan J, Wang C, Gao Q. Yang X, et al. Among authors: zhu ax. Cancer Cell. 2024 Feb 12;42(2):180-197. doi: 10.1016/j.ccell.2024.01.007. Cancer Cell. 2024. PMID: 38350421 Review.
Short-term outcomes of complete mesocolic excision versus D2 dissection in patients undergoing laparoscopic colectomy for right colon cancer (RELARC): a randomised, controlled, phase 3, superiority trial.
Xu L, Su X, He Z, Zhang C, Lu J, Zhang G, Sun Y, Du X, Chi P, Wang Z, Zhong M, Wu A, Zhu A, Li F, Xu J, Kang L, Suo J, Deng H, Ye Y, Ding K, Xu T, Zhang Z, Zheng M, Xiao Y; RELARC Study Group. Xu L, et al. Among authors: zhu a. Lancet Oncol. 2021 Mar;22(3):391-401. doi: 10.1016/S1470-2045(20)30685-9. Epub 2021 Feb 12. Lancet Oncol. 2021. PMID: 33587893 Clinical Trial.
Structures and mechanisms of the Arabidopsis auxin transporter PIN3.
Su N, Zhu A, Tao X, Ding ZJ, Chang S, Ye F, Zhang Y, Zhao C, Chen Q, Wang J, Zhou CY, Guo Y, Jiao S, Zhang S, Wen H, Ma L, Ye S, Zheng SJ, Yang F, Wu S, Guo J. Su N, et al. Among authors: zhu a. Nature. 2022 Sep;609(7927):616-621. doi: 10.1038/s41586-022-05142-w. Epub 2022 Aug 2. Nature. 2022. PMID: 35917926
2,555 results